318 related articles for article (PubMed ID: 8126502)
1. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
Merello M; Lees AJ; Webster R; Bovingdon M; Gordin A
J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):186-9. PubMed ID: 8126502
[TBL] [Abstract][Full Text] [Related]
2. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
3. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
4. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Ruottinen HM; Rinne UK
Clin Neuropharmacol; 1996 Jun; 19(3):222-33. PubMed ID: 8726541
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
6. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
7. Entacapone in the management of Parkinson's disease.
Henchcliffe C; Waters C
Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
[TBL] [Abstract][Full Text] [Related]
8. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
9. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Muhlack S; Herrmann L; Salmen S; Müller T
J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
11. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
Rinne UK; Larsen JP; Siden A; Worm-Petersen J
Neurology; 1998 Nov; 51(5):1309-14. PubMed ID: 9818851
[TBL] [Abstract][Full Text] [Related]
12. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
Kulisevsky J
Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
[TBL] [Abstract][Full Text] [Related]
13. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Brooks DJ; Sagar H;
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
[TBL] [Abstract][Full Text] [Related]
14. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
15. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
17. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
18. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Kaakkola S; Teräväinen H; Ahtila S; Rita H; Gordin A
Neurology; 1994 Jan; 44(1):77-80. PubMed ID: 8290096
[TBL] [Abstract][Full Text] [Related]
19. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
Ruottinen HM; Rinne UK
Clin Neuropharmacol; 1996 Aug; 19(4):283-96. PubMed ID: 8828991
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
